View Future GrowthMedCap 過去の業績過去 基準チェック /36MedCapは、平均年間22.5%の収益成長を遂げていますが、 Life Sciences業界の収益は、年間 成長しています。収益は、平均年間4.4% 19.8%収益成長率で 成長しています。 MedCapの自己資本利益率は14.8%であり、純利益率は10.4%です。主要情報22.51%収益成長率22.27%EPS成長率Life Sciences 業界の成長26.83%収益成長率19.84%株主資本利益率14.79%ネット・マージン10.35%次回の業績アップデート21 Jul 2026最近の業績更新お知らせ • Feb 06MedCap AB (publ) to Report Fiscal Year 2026 Results on Feb 05, 2027MedCap AB (publ) announced that they will report fiscal year 2026 results on Feb 05, 2027お知らせ • Oct 25MedCap AB (publ) to Report Q3, 2026 Results on Oct 23, 2026MedCap AB (publ) announced that they will report Q3, 2026 results on Oct 23, 2026お知らせ • Jul 24+ 2 more updatesMedCap AB (publ) to Report Q1, 2026 Results on Apr 29, 2026MedCap AB (publ) announced that they will report Q1, 2026 results on Apr 29, 2026お知らせ • Feb 02MedCap AB (publ) to Report Q3, 2025 Results on Oct 24, 2025MedCap AB (publ) announced that they will report Q3, 2025 results on Oct 24, 2025Reported Earnings • Oct 26Third quarter 2024 earnings released: EPS: kr3.57 (vs kr2.59 in 3Q 2023)Third quarter 2024 results: EPS: kr3.57 (up from kr2.59 in 3Q 2023). Revenue: kr426.0m (up 17% from 3Q 2023). Net income: kr52.9m (up 38% from 3Q 2023). Profit margin: 12% (up from 11% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.Reported Earnings • Jul 25Second quarter 2024 earnings released: EPS: kr3.84 (vs kr3.16 in 2Q 2023)Second quarter 2024 results: EPS: kr3.84 (up from kr3.16 in 2Q 2023). Revenue: kr469.9m (up 22% from 2Q 2023). Net income: kr56.8m (up 21% from 2Q 2023). Profit margin: 12% (in line with 2Q 2023). Over the last 3 years on average, earnings per share has increased by 35% per year whereas the company’s share price has increased by 32% per year.すべての更新を表示Recent updatesBuy Or Sell Opportunity • Jul 07Now 20% undervaluedOver the last 90 days, the stock has risen 11% to €47.42. The fair value is estimated to be €59.38, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 14%. Revenue is forecast to grow by 18% in 2 years. Earnings are forecast to grow by 40% in the next 2 years.Buy Or Sell Opportunity • Jun 11Now 20% undervaluedOver the last 90 days, the stock has risen 3.6% to €45.94. The fair value is estimated to be €57.59, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 14%. Revenue is forecast to grow by 15% in 2 years. Earnings are forecast to grow by 41% in the next 2 years.Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Otto Ankarcrona was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Mar 31MedCap AB (publ), Annual General Meeting, May 04, 2026MedCap AB (publ), Annual General Meeting, May 04, 2026, at 16:00 W. Europe Standard Time. Location: at iva, grev turegatan 16 in stockholm, stockholm Swedenお知らせ • Feb 06MedCap AB (publ) to Report Fiscal Year 2026 Results on Feb 05, 2027MedCap AB (publ) announced that they will report fiscal year 2026 results on Feb 05, 2027お知らせ • Oct 25MedCap AB (publ) to Report Q3, 2026 Results on Oct 23, 2026MedCap AB (publ) announced that they will report Q3, 2026 results on Oct 23, 2026お知らせ • Jul 24+ 2 more updatesMedCap AB (publ) to Report Q1, 2026 Results on Apr 29, 2026MedCap AB (publ) announced that they will report Q1, 2026 results on Apr 29, 2026お知らせ • Jun 25MedCap AB (publ) (OM:MCAP) acquired XGX PharmaMedCap AB (publ) (OM:MCAP) agreed to acquire XGX Pharma on June 25, 2025. MedCap AB (publ) (OM:MCAP) completed acquisition of XGX Pharma on June 25, 2025.お知らせ • May 10MedCap AB (publ) (OM:MCAP) announces an Equity Buyback for SEK 26 million worth of its shares.MedCap AB (publ) (OM:MCAP) announces a share repurchase program. Under the program, the company will repurchase up to SEK 26 million worth of its shares. The shares shall be acquired at a price per share within the price range applicable on Nasdaq Stockholm at any time, which refers to the interval between the highest bid price and the lowest ask price published continuously by Nasdaq Stockholm. The purpose of the program is to secure the Company's commitment to share-based incentive programs (LTIP 2025/2028) through holdings of unvested shares and to continuously adapt the Company's capital structure to the Company's capital needs and thereby contribute to increased shareholder value, and to enable future acquisitions of companies or businesses to be made through payment with own shares. The program will be valid till August 29, 2025. As of May 7, 2025, the company had 14,981,353 outstanding shares and 0 treasury shares.お知らせ • Apr 03MedCap AB (publ), Annual General Meeting, May 05, 2025MedCap AB (publ), Annual General Meeting, May 05, 2025, at 16:00 W. Europe Standard Time. Location: iva, grev turegatan 16, stockholm Swedenお知らせ • Feb 02MedCap AB (publ) to Report Q3, 2025 Results on Oct 24, 2025MedCap AB (publ) announced that they will report Q3, 2025 results on Oct 24, 2025Reported Earnings • Oct 26Third quarter 2024 earnings released: EPS: kr3.57 (vs kr2.59 in 3Q 2023)Third quarter 2024 results: EPS: kr3.57 (up from kr2.59 in 3Q 2023). Revenue: kr426.0m (up 17% from 3Q 2023). Net income: kr52.9m (up 38% from 3Q 2023). Profit margin: 12% (up from 11% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Jul 31Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €52.00, the stock trades at a trailing P/E ratio of 41.7x. Average trailing P/E is 43x in the Life Sciences industry in Europe. Total returns to shareholders of 146% over the past three years.Reported Earnings • Jul 25Second quarter 2024 earnings released: EPS: kr3.84 (vs kr3.16 in 2Q 2023)Second quarter 2024 results: EPS: kr3.84 (up from kr3.16 in 2Q 2023). Revenue: kr469.9m (up 22% from 2Q 2023). Net income: kr56.8m (up 21% from 2Q 2023). Profit margin: 12% (in line with 2Q 2023). Over the last 3 years on average, earnings per share has increased by 35% per year whereas the company’s share price has increased by 32% per year.お知らせ • Jul 25MedCap AB (publ) to Report Q2, 2025 Results on Jul 23, 2025MedCap AB (publ) announced that they will report Q2, 2025 results on Jul 23, 2025New Risk • Jul 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Buy Or Sell Opportunity • Jul 01Now 17% undervaluedOver the last 90 days, the stock has risen 36% to €44.05. The fair value is estimated to be €53.33, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 34%.Buy Or Sell Opportunity • Jun 26Now 21% undervaluedOver the last 90 days, the stock has risen 35% to €45.35. The fair value is estimated to be €57.29, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 34%.お知らせ • May 12MedCap AB (publ) to Report Q1, 2025 Results on Apr 29, 2025MedCap AB (publ) announced that they will report Q1, 2025 results on Apr 29, 2025Reported Earnings • May 03First quarter 2024 earnings released: EPS: kr3.78 (vs kr1.68 in 1Q 2023)First quarter 2024 results: EPS: kr3.78 (up from kr1.68 in 1Q 2023). Revenue: kr463.1m (up 22% from 1Q 2023). Net income: kr56.0m (up 126% from 1Q 2023). Profit margin: 12% (up from 6.5% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth.お知らせ • Apr 03MedCap AB (publ), Annual General Meeting, May 06, 2024MedCap AB (publ), Annual General Meeting, May 06, 2024.お知らせ • Mar 29MedCap AB (publ) to Report Fiscal Year 2024 Results on Jan 31, 2025MedCap AB (publ) announced that they will report fiscal year 2024 results on Jan 31, 2025Reported Earnings • Feb 02Full year 2023 earnings released: EPS: kr11.63 (vs kr7.94 in FY 2022)Full year 2023 results: EPS: kr11.63 (up from kr7.94 in FY 2022). Revenue: kr1.60b (up 43% from FY 2022). Net income: kr172.2m (up 46% from FY 2022). Profit margin: 11% (in line with FY 2022).Valuation Update With 7 Day Price Move • Feb 01Investor sentiment improves as stock rises 18%After last week's 18% share price gain to €33.10, the stock trades at a trailing P/E ratio of 37.4x. Average trailing P/E is 44x in the Life Sciences industry in Europe. Total returns to shareholders of 66% over the past year.お知らせ • Oct 29MedCap AB (publ) to Report Q3, 2024 Results on Oct 25, 2024MedCap AB (publ) announced that they will report Q3, 2024 results on Oct 25, 2024Reported Earnings • Oct 29Third quarter 2023 earnings released: EPS: kr2.59 (vs kr2.47 in 3Q 2022)Third quarter 2023 results: EPS: kr2.59 (up from kr2.47 in 3Q 2022). Revenue: kr368.2m (up 52% from 3Q 2022). Net income: kr38.3m (up 4.6% from 3Q 2022). Profit margin: 10% (down from 15% in 3Q 2022). The decrease in margin was driven by higher expenses.お知らせ • Jul 31MedCap AB (publ) to Report First Half, 2024 Results on Jul 19, 2024MedCap AB (publ) announced that they will report first half, 2024 results on Jul 19, 2024Reported Earnings • Jul 29Second quarter 2023 earnings released: EPS: kr3.16 (vs kr1.42 in 2Q 2022)Second quarter 2023 results: EPS: kr3.16 (up from kr1.42 in 2Q 2022). Revenue: kr390.0m (up 37% from 2Q 2022). Net income: kr46.8m (up 123% from 2Q 2022). Profit margin: 12% (up from 7.4% in 2Q 2022). The increase in margin was driven by higher revenue.New Risk • Jul 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.お知らせ • Jul 25MedCap AB (publ) (OM:MCAP) signed an agreement to acquire SurgiCube International B.V. for €8 million.MedCap AB (publ) (OM:MCAP) signed an agreement to acquire Surgicube International B.V. for €8 million on July 24, 2023. Under the transaction, MedCap pays €6 million and adjustments for net debt / cash at closing and an earn-out up to €2 million based on the gross profit growth until December 2024. SurgiCube’s sales in the last 12 months amounted to approximately €3.7 million with almost 24% EBITDA-margin. Key individuals in the business have committed to remain as minority owners, and the former majority owner Ger Vijfvinkel has committed to remain as managing director and then as advisor during a transition phase.お知らせ • May 05MedCap AB (publ) to Report Q1, 2024 Results on May 03, 2024MedCap AB (publ) announced that they will report Q1, 2024 results on May 03, 2024Reported Earnings • May 03First quarter 2023 earnings released: EPS: kr1.68 (vs kr1.32 in 1Q 2022)First quarter 2023 results: EPS: kr1.68 (up from kr1.32 in 1Q 2022). Revenue: kr384.0m (up 46% from 1Q 2022). Net income: kr24.8m (up 27% from 1Q 2022). Profit margin: 6.5% (down from 7.5% in 1Q 2022). The decrease in margin was driven by higher expenses.Reported Earnings • Feb 12Full year 2022 earnings released: EPS: kr7.94 (vs kr6.52 in FY 2021)Full year 2022 results: EPS: kr7.94 (up from kr6.52 in FY 2021). Revenue: kr1.15b (up 24% from FY 2021). Net income: kr117.6m (up 22% from FY 2021). Profit margin: 10% (in line with FY 2021).Board Change • Nov 28High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 5 experienced directors. 1 highly experienced director. Independent Director Anders Hansen is the most experienced director on the board, commencing their role in 2011. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.収支内訳MedCap の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DB:61MA 収益、費用、利益 ( )SEK Millions日付収益収益G+A経費研究開発費31 Mar 262,176225813031 Dec 252,110220792030 Sep 251,996197764030 Jun 251,908199736031 Mar 251,844202720031 Dec 241,807207699030 Sep 241,791228674030 Jun 241,742214655031 Mar 241,671203624031 Dec 231,589172601030 Sep 231,466150562030 Jun 231,343149523031 Mar 231,241123486031 Dec 221,124118444030 Sep 221,056118419030 Jun 221,017107410031 Mar 22967102394031 Dec 2192697385030 Sep 2189676375030 Jun 2186964359031 Mar 2184567339031 Dec 2082863329030 Sep 2080255326030 Jun 2078653317031 Mar 2076347308031 Dec 1975755294030 Sep 1973443288030 Jun 1974041291031 Mar 1972732297031 Dec 1870924298030 Sep 1871614286030 Jun 186898278031 Mar 1866010268031 Dec 176177261031 Oct 1777911298031 Jul 178023301030 Apr 178530299031 Jan 179015291031 Oct 1689710276031 Jul 1687419258030 Apr 1681820239031 Jan 1681718232031 Oct 1581817226031 Jul 1582582280質の高い収益: 61MAは 高品質の収益 を持っています。利益率の向上: 61MAの現在の純利益率 (10.4%)は、昨年(10.9%)よりも低くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 61MAの収益は過去 5 年間で年間22.5%増加しました。成長の加速: 61MAの過去 1 年間の収益成長率 ( 11.5% ) は、5 年間の平均 ( 年間22.5%を下回っています。収益対業界: 61MAの過去 1 年間の収益成長率 ( 11.5% ) はLife Sciences業界8.5%を上回りました。株主資本利益率高いROE: 61MAの 自己資本利益率 ( 14.8% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/17 06:32終値2026/07/17 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋MedCap AB (publ) 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関null nullABG Sundal CollierBjorn RydellABG Sundal Collier SponsoredHans MählerNordea Markets2 その他のアナリストを表示
お知らせ • Feb 06MedCap AB (publ) to Report Fiscal Year 2026 Results on Feb 05, 2027MedCap AB (publ) announced that they will report fiscal year 2026 results on Feb 05, 2027
お知らせ • Oct 25MedCap AB (publ) to Report Q3, 2026 Results on Oct 23, 2026MedCap AB (publ) announced that they will report Q3, 2026 results on Oct 23, 2026
お知らせ • Jul 24+ 2 more updatesMedCap AB (publ) to Report Q1, 2026 Results on Apr 29, 2026MedCap AB (publ) announced that they will report Q1, 2026 results on Apr 29, 2026
お知らせ • Feb 02MedCap AB (publ) to Report Q3, 2025 Results on Oct 24, 2025MedCap AB (publ) announced that they will report Q3, 2025 results on Oct 24, 2025
Reported Earnings • Oct 26Third quarter 2024 earnings released: EPS: kr3.57 (vs kr2.59 in 3Q 2023)Third quarter 2024 results: EPS: kr3.57 (up from kr2.59 in 3Q 2023). Revenue: kr426.0m (up 17% from 3Q 2023). Net income: kr52.9m (up 38% from 3Q 2023). Profit margin: 12% (up from 11% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Jul 25Second quarter 2024 earnings released: EPS: kr3.84 (vs kr3.16 in 2Q 2023)Second quarter 2024 results: EPS: kr3.84 (up from kr3.16 in 2Q 2023). Revenue: kr469.9m (up 22% from 2Q 2023). Net income: kr56.8m (up 21% from 2Q 2023). Profit margin: 12% (in line with 2Q 2023). Over the last 3 years on average, earnings per share has increased by 35% per year whereas the company’s share price has increased by 32% per year.
Buy Or Sell Opportunity • Jul 07Now 20% undervaluedOver the last 90 days, the stock has risen 11% to €47.42. The fair value is estimated to be €59.38, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 14%. Revenue is forecast to grow by 18% in 2 years. Earnings are forecast to grow by 40% in the next 2 years.
Buy Or Sell Opportunity • Jun 11Now 20% undervaluedOver the last 90 days, the stock has risen 3.6% to €45.94. The fair value is estimated to be €57.59, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 14%. Revenue is forecast to grow by 15% in 2 years. Earnings are forecast to grow by 41% in the next 2 years.
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Otto Ankarcrona was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Mar 31MedCap AB (publ), Annual General Meeting, May 04, 2026MedCap AB (publ), Annual General Meeting, May 04, 2026, at 16:00 W. Europe Standard Time. Location: at iva, grev turegatan 16 in stockholm, stockholm Sweden
お知らせ • Feb 06MedCap AB (publ) to Report Fiscal Year 2026 Results on Feb 05, 2027MedCap AB (publ) announced that they will report fiscal year 2026 results on Feb 05, 2027
お知らせ • Oct 25MedCap AB (publ) to Report Q3, 2026 Results on Oct 23, 2026MedCap AB (publ) announced that they will report Q3, 2026 results on Oct 23, 2026
お知らせ • Jul 24+ 2 more updatesMedCap AB (publ) to Report Q1, 2026 Results on Apr 29, 2026MedCap AB (publ) announced that they will report Q1, 2026 results on Apr 29, 2026
お知らせ • Jun 25MedCap AB (publ) (OM:MCAP) acquired XGX PharmaMedCap AB (publ) (OM:MCAP) agreed to acquire XGX Pharma on June 25, 2025. MedCap AB (publ) (OM:MCAP) completed acquisition of XGX Pharma on June 25, 2025.
お知らせ • May 10MedCap AB (publ) (OM:MCAP) announces an Equity Buyback for SEK 26 million worth of its shares.MedCap AB (publ) (OM:MCAP) announces a share repurchase program. Under the program, the company will repurchase up to SEK 26 million worth of its shares. The shares shall be acquired at a price per share within the price range applicable on Nasdaq Stockholm at any time, which refers to the interval between the highest bid price and the lowest ask price published continuously by Nasdaq Stockholm. The purpose of the program is to secure the Company's commitment to share-based incentive programs (LTIP 2025/2028) through holdings of unvested shares and to continuously adapt the Company's capital structure to the Company's capital needs and thereby contribute to increased shareholder value, and to enable future acquisitions of companies or businesses to be made through payment with own shares. The program will be valid till August 29, 2025. As of May 7, 2025, the company had 14,981,353 outstanding shares and 0 treasury shares.
お知らせ • Apr 03MedCap AB (publ), Annual General Meeting, May 05, 2025MedCap AB (publ), Annual General Meeting, May 05, 2025, at 16:00 W. Europe Standard Time. Location: iva, grev turegatan 16, stockholm Sweden
お知らせ • Feb 02MedCap AB (publ) to Report Q3, 2025 Results on Oct 24, 2025MedCap AB (publ) announced that they will report Q3, 2025 results on Oct 24, 2025
Reported Earnings • Oct 26Third quarter 2024 earnings released: EPS: kr3.57 (vs kr2.59 in 3Q 2023)Third quarter 2024 results: EPS: kr3.57 (up from kr2.59 in 3Q 2023). Revenue: kr426.0m (up 17% from 3Q 2023). Net income: kr52.9m (up 38% from 3Q 2023). Profit margin: 12% (up from 11% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Jul 31Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €52.00, the stock trades at a trailing P/E ratio of 41.7x. Average trailing P/E is 43x in the Life Sciences industry in Europe. Total returns to shareholders of 146% over the past three years.
Reported Earnings • Jul 25Second quarter 2024 earnings released: EPS: kr3.84 (vs kr3.16 in 2Q 2023)Second quarter 2024 results: EPS: kr3.84 (up from kr3.16 in 2Q 2023). Revenue: kr469.9m (up 22% from 2Q 2023). Net income: kr56.8m (up 21% from 2Q 2023). Profit margin: 12% (in line with 2Q 2023). Over the last 3 years on average, earnings per share has increased by 35% per year whereas the company’s share price has increased by 32% per year.
お知らせ • Jul 25MedCap AB (publ) to Report Q2, 2025 Results on Jul 23, 2025MedCap AB (publ) announced that they will report Q2, 2025 results on Jul 23, 2025
New Risk • Jul 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Buy Or Sell Opportunity • Jul 01Now 17% undervaluedOver the last 90 days, the stock has risen 36% to €44.05. The fair value is estimated to be €53.33, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 34%.
Buy Or Sell Opportunity • Jun 26Now 21% undervaluedOver the last 90 days, the stock has risen 35% to €45.35. The fair value is estimated to be €57.29, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 34%.
お知らせ • May 12MedCap AB (publ) to Report Q1, 2025 Results on Apr 29, 2025MedCap AB (publ) announced that they will report Q1, 2025 results on Apr 29, 2025
Reported Earnings • May 03First quarter 2024 earnings released: EPS: kr3.78 (vs kr1.68 in 1Q 2023)First quarter 2024 results: EPS: kr3.78 (up from kr1.68 in 1Q 2023). Revenue: kr463.1m (up 22% from 1Q 2023). Net income: kr56.0m (up 126% from 1Q 2023). Profit margin: 12% (up from 6.5% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth.
お知らせ • Apr 03MedCap AB (publ), Annual General Meeting, May 06, 2024MedCap AB (publ), Annual General Meeting, May 06, 2024.
お知らせ • Mar 29MedCap AB (publ) to Report Fiscal Year 2024 Results on Jan 31, 2025MedCap AB (publ) announced that they will report fiscal year 2024 results on Jan 31, 2025
Reported Earnings • Feb 02Full year 2023 earnings released: EPS: kr11.63 (vs kr7.94 in FY 2022)Full year 2023 results: EPS: kr11.63 (up from kr7.94 in FY 2022). Revenue: kr1.60b (up 43% from FY 2022). Net income: kr172.2m (up 46% from FY 2022). Profit margin: 11% (in line with FY 2022).
Valuation Update With 7 Day Price Move • Feb 01Investor sentiment improves as stock rises 18%After last week's 18% share price gain to €33.10, the stock trades at a trailing P/E ratio of 37.4x. Average trailing P/E is 44x in the Life Sciences industry in Europe. Total returns to shareholders of 66% over the past year.
お知らせ • Oct 29MedCap AB (publ) to Report Q3, 2024 Results on Oct 25, 2024MedCap AB (publ) announced that they will report Q3, 2024 results on Oct 25, 2024
Reported Earnings • Oct 29Third quarter 2023 earnings released: EPS: kr2.59 (vs kr2.47 in 3Q 2022)Third quarter 2023 results: EPS: kr2.59 (up from kr2.47 in 3Q 2022). Revenue: kr368.2m (up 52% from 3Q 2022). Net income: kr38.3m (up 4.6% from 3Q 2022). Profit margin: 10% (down from 15% in 3Q 2022). The decrease in margin was driven by higher expenses.
お知らせ • Jul 31MedCap AB (publ) to Report First Half, 2024 Results on Jul 19, 2024MedCap AB (publ) announced that they will report first half, 2024 results on Jul 19, 2024
Reported Earnings • Jul 29Second quarter 2023 earnings released: EPS: kr3.16 (vs kr1.42 in 2Q 2022)Second quarter 2023 results: EPS: kr3.16 (up from kr1.42 in 2Q 2022). Revenue: kr390.0m (up 37% from 2Q 2022). Net income: kr46.8m (up 123% from 2Q 2022). Profit margin: 12% (up from 7.4% in 2Q 2022). The increase in margin was driven by higher revenue.
New Risk • Jul 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
お知らせ • Jul 25MedCap AB (publ) (OM:MCAP) signed an agreement to acquire SurgiCube International B.V. for €8 million.MedCap AB (publ) (OM:MCAP) signed an agreement to acquire Surgicube International B.V. for €8 million on July 24, 2023. Under the transaction, MedCap pays €6 million and adjustments for net debt / cash at closing and an earn-out up to €2 million based on the gross profit growth until December 2024. SurgiCube’s sales in the last 12 months amounted to approximately €3.7 million with almost 24% EBITDA-margin. Key individuals in the business have committed to remain as minority owners, and the former majority owner Ger Vijfvinkel has committed to remain as managing director and then as advisor during a transition phase.
お知らせ • May 05MedCap AB (publ) to Report Q1, 2024 Results on May 03, 2024MedCap AB (publ) announced that they will report Q1, 2024 results on May 03, 2024
Reported Earnings • May 03First quarter 2023 earnings released: EPS: kr1.68 (vs kr1.32 in 1Q 2022)First quarter 2023 results: EPS: kr1.68 (up from kr1.32 in 1Q 2022). Revenue: kr384.0m (up 46% from 1Q 2022). Net income: kr24.8m (up 27% from 1Q 2022). Profit margin: 6.5% (down from 7.5% in 1Q 2022). The decrease in margin was driven by higher expenses.
Reported Earnings • Feb 12Full year 2022 earnings released: EPS: kr7.94 (vs kr6.52 in FY 2021)Full year 2022 results: EPS: kr7.94 (up from kr6.52 in FY 2021). Revenue: kr1.15b (up 24% from FY 2021). Net income: kr117.6m (up 22% from FY 2021). Profit margin: 10% (in line with FY 2021).
Board Change • Nov 28High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 5 experienced directors. 1 highly experienced director. Independent Director Anders Hansen is the most experienced director on the board, commencing their role in 2011. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.